Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Humira adalimumab: Marketed

November 3, 2003 8:00 AM UTC

Updated data from 3 double-blind Phase III trials showed Humira 40 mg every other week plus methotrexate significantly decreased the mean HAQ Disability Index in each trial at 24 weeks compared to pla...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article